ArticleFuture oncology (London, England)2025
Prognostic role of prognostic nutritional index in patients with lymphoma-associated hemophagocytic lymphohistiocytosis.
Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsLymphoma-associated hemophagocytic lymphohistiocytosis (LA-HLH) is a rare and life-threatening disorder. While the prognostic nutritional index (PNI) has been recognized as an independent prognostic indicator in lymphoma studies, its specific role in LA-HLH has not yet been reported.
methodsWe retrospectively examined clinical characteristics and prognostic factors from 124 LA-HLH patients.
results23 patients (18.5%) had B-cell lymphoma-associated HLH (B-LA-HLH), and 101 cases presented with T or natural killer (NK)-cell lymphoma-associated HLH (T/NK-LA-HLH). The median survival time for the entire group was two months, with T/NK-LA-HLH and B-LA-HLH showing median survival times of 1.6 months and 5.0 months, respectively, post-HLH diagnosis. The optimal threshold for the prognostic nutritional index (PNI) was 35.5. Analysis of prognostic factors indicated that the HLH onset at lymphoma relapse and a PNI below 35.5 were independent predictors of inferior overall survival. Patients with a PNI below 35.5 had a significantly shorter estimated survival duration than those with a PNI of 35.5 or higher (
conclusionsThe onset of HLH at lymphoma relapse and a low PNI may be considered adverse prognostic indicators for LA-HLH, potentially aiding in risk stratification and informing clinical decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.